Top

Published in:

17-02-2024 | Neutropenia | RESEARCH

Serum interleukin-33 and soluble suppression of tumorigenicity 2 in pediatric leukemia with febrile neutropenia

Authors: Merve Cansu Polat, Çiğdem Sönmez, Neşe Yarali, Namık Yaşar Özbek

Published in: European Journal of Pediatrics | Issue 5/2024

Abstract

The purpose of this study was to evaluate the association between interleukin-33 (IL-33) and its receptor Soluble Suppression of Tumorigenicity-2 (sST2) levels and bacterial infections during febrile neutropenia (FN) in pediatric patients with acute lymphoblastic leukemia (ALL). In this prospective, case–control study, participants were divided into 3 groups: ALL patients with FN (Group A), ALL patients without neutropenia and fever (Group B), and healthy children without infection and chronic disease (Group C). There were 30 cases in each group. Blood samples for IL-33 and sST2 have been drawn from patients in Group A before the initiation of treatment and on days 1 and 5 of treatment, and from patients in Groups B and C at initiation. At admission, mean IL-33 level (39.02 ± 26.40 ng/L) in Group B and mean sST2 level (185.3 ± 371.49 ng/ml) in Group A were significantly higher than the other groups (p = 0.038, p < 0.001, respectively). No difference was observed in the mean IL-33 and sST2 levels in the 5-day follow-up of patients in Group A (p = 0.82, p = 0.86, respectively). IL-33 and sST2 levels were not associated with fever duration, neutropenia duration or length of hospitalization. While C-reactive protein (CRP) was significantly higher in patients with positive blood culture (p = 0.021), IL-33 (p = 0.49) and sST2 (p = 0.21) levels were not associated with culture positivity.

Conclusion: IL-33 and sST2 levels were not found valuable as diagnostic and prognostic markers to predict bacterial sepsis in patients with FN.

What is Known: • Neutropenic patients are at high risk of serious bacterial and viral infections, but the admission symptom is often only fever. • Febrile neutropenia has a high mortality rate if not treated effectively.
What is New: • Febrile neutropenia is not only caused by bacterial infections. Therefore, new biomarkers should be identified to prevent overuse of antibiotics. • Specific biomarkers are needed to diagnose bacterial sepsis in the early phase of febrile neutropenia.

Bhojwani D, Yang JJ, Pui CH (2015) Biology of Childhood Acute Lymphoblastic Leukemia. Pediatr Clin North Am 62(1):47–60. https://doi.org/10.1016/j.pcl.2014.09.004CrossRefPubMedPubMedCentral

Ward E, DeSantis C, Robbins A, Kohler B, Jemal A (2014) Childhood and adolescent cancer statistics. CA Cancer J Clin 64(2):83–103. https://doi.org/10.3322/caac.21219CrossRefPubMed

Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):56–93. https://doi.org/10.1093/cid/cir073CrossRef

Crokaert F (2000) Febrile neutropenia in children. Int J Antimicrob Agents 16:173–176. https://doi.org/10.1016/s0924-8579(00)00239-9CrossRefPubMed

Riikonen P, Saarinen UM, Metsärinne TA, K, Fyhrquist F, Jalanko H, (1992) Cytokine and Acute-Phase Reactant Levels in Serum of Children with Cancer Admitted for Fever and Neutropenia. J Infect Dis 166(2):432–436. https://doi.org/10.1093/infdis/166.2.432CrossRefPubMed

Ebihara Y, Kobayashi K, Ishida A, Maeda T, Takahashi N, Taji Y et al (2017) Diagnostic performance of procalcitonin, presepsin, and reactive protein in patients with hematological malignancies. J Clin Lab Anal 31(6):1–7. https://doi.org/10.1002/jcla.22147CrossRef

Michel CS, Teschner D, Wagner EM, Theobald M, Radsak MP (2017) Diagnostic value of sTREM-1, IL-8, PCT, and CRP in febrile neutropenia after autologous stem cell transplantation. Ann Hematol 96(12):2095–2101. https://doi.org/10.1007/s00277-017-3128-1CrossRefPubMed

Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N et al (2012) IL-33 / ST2 axis in inflammation and immunopathology. Immunol Res 52(1–2):89–99. https://doi.org/10.1007/s12026-012-8283-9CrossRefPubMed

Xu H, Turnquist HR, Hoffman R, Billiar TR (2017) Role of the IL-33-ST2 axis in sepsis. Mil Med Res 2(4:3)1–9. https://doi.org/10.1186/s40779-017-0115-8

10.

De la Fuente M, Macdonald TT, Hermoso MA (2015) The IL-33 / ST2 axis: Role in health and disease. Cytokine Growth Factor Rev 26(6):615–623. https://doi.org/10.1016/j.cytogfr.2015.07.017CrossRefPubMed

11.

Cayrol C, Girard JP (2018) Interleukin- 33 (IL- 33): A nuclear cytokine from the IL- 1 family. Immunol Rev 281(1):154–168. https://doi.org/10.1111/imr.12619CrossRefPubMed

12.

Kurowska M, Hueber A, Stolarski B (2011) Interleukin-33: a novel mediator with a role in distinct disease pathologies. J Intern Med 269(1):29–35. https://doi.org/10.1111/j.1365-2796.2010.02316.xCrossRef

13.

Palmer G, Gabay C (2011) Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 7(6):321–329. https://doi.org/10.1038/nrrheum.2011.53CrossRefPubMed

14.

Pei C, Barbour M, Fairlie-Clarke KJ, Allan D, Mu R, Jiang HR (2014) Emerging role of interleukin-33 in autoimmune diseases. Immunology 141(1):9–17. https://doi.org/10.1111/imm.12174CrossRefPubMed

15.

Griesenauer B, Paczesny S (2017) The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front Immunol 8:475. https://doi.org/10.3389/fimmu.2017.00475CrossRefPubMedPubMedCentral

16.

Musolino C, Allegra A, Profita M, Alonci A, Saitta S, Bonanno A et al (2014) Reduction in IL-33 Plasma Levels Might Be Involved in T Cell Dysregulation in Chronic Lymphocytic Leukemia. Acta Haematol 131(3):165–166. https://doi.org/10.1159/000353476CrossRefPubMed

17.

Qin L, Dominguez D, Chen S, Fan J, Long A, Zhang M et al (2016) Exogenous IL-33 overcomes T cell 83 tolerance in murine acute myeloid leukemia. Oncotarget 20;7(38):61069–61080. https://doi.org/10.18632/oncotarget.11179

18.

Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al (2002) 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. Clin Infect Dis 34(6):730–751. https://doi.org/10.1086/339215CrossRefPubMed

19.

Pulcini CD, Lentz S, Saladino RA, Bounds R, Herrington R, Michaels MG et al (2021) Emergency management of fever and neutropenia in children with cancer: A review. Am J Emerg Med 50:693–698. https://doi.org/10.1016/j.ajem.2021.09.055CrossRefPubMed

20.

Buchheidt D, Böhme A, Fätkenheuer COA, G, Fuhr HG, Heussel G, et al (2003) Diagnosis and treatment of documented infections in neutropenic patients Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 8(2):127–312. https://doi.org/10.1007/s00277-003-0766-2CrossRef

21.

Boccia R, Glaspy J, Crawford J, Aapro M (2022) Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?. Oncologist 5;27(8):625–36. https://doi.org/10.1093/oncolo/oyac074

22.

Bakhshi S, Padmanjali KS, Arya LS (2008) An Analysis of 222 Febrile Neutropenic Episodes. Pediatr Hematol Oncol 25(5):385–392. https://doi.org/10.1080/08880010802106564CrossRefPubMed

23.

Giamarellou H, Antoniadou A (2001) Infectious Complications of Febrile Leukopenia. Infect Dis Clin North Am 15(2):457–82. https://doi.org/10.1016/s0891-5520(05)70156-2

24.

Viscoli C, Varnier O, Machetti M (2005) Infections in Patients with Febrile Neutropenia: Epidemiology, Microbiology and Risk Stratification. Clin Infect Dis 1(40):240–245. https://doi.org/10.1086/427329CrossRef

25.

Castagnola E, Fontano V, Caviglia I, Caruso S, Faraci M, Fioredda F et al (2007) A Prospective Study on the Epidemiology of Febrile Episodes during Chemotherapy-Induced Neutropenia in Children with Cancer or after Hemopoietic Stem Cell Transplantation. Clin Infect Dis 15;45(10):1296–304. https://doi.org/10.1086/522533

26.

Baysallar M, Güçlü AÜ, Şenses Z, Kaptan K, Ataergin S (2007) Başustaoğlu AC (2007) Febril nötropenik hastaların kan kültürlerinde bakteriyel spektrum ve antimikrobiyal duyarlılık profili. Gülhane Tıp Dergisi 49:168–172

27.

Lindblom A, Bhadri V, Söderhäll S, Ohrmalm L, Wong M, Norbeck O et al (2010) Respiratory viruses, a common microbiological finding in neutropenic children with fever. J Clin Virol 47(3):234–237. https://doi.org/10.1016/j.jcv.2009.11.026CrossRefPubMedPubMedCentral

28.

Meier-ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM (2001) Absence of Diurnal Variation of C-Reactive Protein Concentrations in Healthy Human Subjects. Clin Chem 47(3):426–430CrossRefPubMed

29.

Lu D, Zhou X, Yao L, Liu CG, Ma W, Jin F et al (2014) Serum soluble ST2 is associated with ER-positive breast cancer. BMC Cancer 18(14):198. https://doi.org/10.1186/1471-2407-14-198CrossRef

30.

Vu D, Peck AJ, Nichols WG, Varley C, Englund JA, Corey L et al (2007) Safety and Tolerability of Oseltamivir Prophylaxis in Hematopoietic Stem Cell Transplant Recipients: A Retrospective Case-Control Study. Clin Infect Dis 15;45(2):187–93. https://doi.org/10.1086/518985

31.

Hu L, Fu Y, Zhang D, Zhang J (2013) Serum IL-33 as a Diagnostic and Prognostic Marker in Non- small Cell Lung Cancer. Asian Pac J Cancer Prev 14(4):2563–2566. https://doi.org/10.7314/apjcp.2013.14.4.2563CrossRefPubMed

32.

Sun P, Ben Q, Tu S, Qi X, Wu Y (2011) Serum Interleukin-33 Levels in Patients with Gastric Cancer. Dig Dis Sci 56(12):3596–3601. https://doi.org/10.1007/s10620-011-1760-5CrossRefPubMed

33.

Hoogerwerf JJ, Tanck MWT, van Zoelen MAD, Wittebole X, Laterre PF, van der Poll T (2010) Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med 36(4):630–637. https://doi.org/10.1007/s00134-010-1773-0CrossRefPubMedPubMedCentral

34.

Çekmez F, Fidanci MK, Ayar G, Saldir M, Karaoglu A, Gündüz RC et al (2016) Diagnostic Value of Upar, IL-33, and ST2 Levels in Childhood Sepsis. Clin Lab 62(5):751–755. https://doi.org/10.7754/clin.lab.2014.141013CrossRefPubMed

Title: Serum interleukin-33 and soluble suppression of tumorigenicity 2 in pediatric leukemia with febrile neutropenia
Authors: Merve Cansu Polat
Çiğdem Sönmez
Neşe Yarali
Namık Yaşar Özbek
Publication date: 17-02-2024
Publisher: Springer Berlin Heidelberg
Keywords: Neutropenia
Acute Lymphoblastic Leukemia
Leukemia
Septicemia
Septicemia
Published in: European Journal of Pediatrics / Issue 5/2024
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-024-05478-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum interleukin-33 and soluble suppression of tumorigenicity 2 in pediatric leukemia with febrile neutropenia

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2024

Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study

Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study

A significant increase in anthropometric indices during long-term follow-up of pediatric patients with celiac disease, with no endocrine disorders

Risk factors for infant hearing loss: a meta-analysis

Determining the state of guidance on pediatric biobanking for researchers, HRECS, and families: Regulatory mapping of international guidance

Shorter versus longer-course of antibiotic therapy for urinary tract infections in pediatric population: an updated meta-analysis